Loading...
 

Volume 28, Issue 1, March 2017

Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2017; 28(1): 58-61
The use of Canakinumab in treating resistant gouty disease in patients with limited therapeutic options: The experience of the Rheumatology Clinic of Asklipeion General Hospital of Voula, Greece
Authors Information
Asklipeion General Hospital of Voula, Athens, Greece
Abstract
Gout is an autoinflammatory disease caused by monosodium urate mono hydrate crystal deposition in tissues or the supersaturation of extracellular fluids of uric acid. In this study, we are going to report the experience of the Asklepeion Voula Rheumatology Clinic, treating four patients with gouty arthritis who received Canakinumab.